Vera Bril
Toronto General Hospital · University Health Network, Toronto
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Vera Bril as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:09 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06587867 · Seronegative Myasthenia Gravis - Efgartigimod IVUniversity Health Network, Toronto · unknown · Efgartigimod, Generalized Myasthenia Gravis · principal investigator
- Ph2NCT02034266 · The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 DiabetesEduardo Ng · completed · Type 1 Diabetes · principal investigator
- Ph4NCT01179893 · Intravenous Immunoglobulin and Plasma Exchange in Myasthenia GravisUniversity Health Network, Toronto · completed · Myasthenia Gravid · principal investigator
- Ph3NCT00306033 · Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia GravisUniversity Health Network, Toronto · completed · Myasthenia Gravis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:09 UTC. The ranking covers the 200 most relevant of 80 PubMed records, and a shared surname and initials can bring in a namesake. All 80 on PubMed
- Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.Lancet Neurol · 2021651 citationsRCR 46.4
- 530 citationsRCR 16.5
- 312 citationsRCR 10.9
- Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.N Engl J Med · 1988306 citationsRCR 11.3
- Comparison of IVIg and PLEX in patients with myasthenia gravis.Neurology · 2011257 citationsRCR 9.2
- Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.Lancet Neurol · 2023248 citationsRCR 31.2
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.Neurology · 2019237 citationsRCR 10.9
- Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol · 2018227 citationsRCR 12.5
- IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.Neurology · 2007187 citationsRCR 5.7
- Detection of diabetic sensorimotor polyneuropathy by corneal confocal microscopy in type 1 diabetes: a concurrent validity study.Diabetes Care · 2012155 citationsRCR 6.3